SAN DIEGO, CA, RayThera, Inc., a recently founded biotechnology company currently focused on discovering and developing small molecule therapies in immunology, announced that it has completed its Series A financing, with a total of $110M raised.
RayThera, Inc., a recently founded biotechnology company currently focused on discovering and developing small molecule therapies in immunology, announced that it has completed its Series A financing, with a total of $110M raised. The financing was co-led by Foresite Capital and OrbiMed Advisors, with participation from TTM Capital. Proceeds from the financing will be used to advance RayThera's lead drug candidates through Phase 1 clinical studies.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
